Eli Lilly Acquires Merida Biosciences in Up to $2.875 Billion Deal to Expand Metabolic Pipeline

The Quick Take

• Eli Lilly has agreed to acquire Merida Biosciences in a deal valued at up to $2.875 billion, further expanding its pharmaceutical pipeline beyond its blockbuster GLP-1 franchise.
• The acquisition reflects Lilly's strategic intent to build a dominant position in cardiometabolic disease treatment, with Merida adding new assets to complement Mounjaro and Zepbound.
• The deal signals continued aggressive M&A activity by leading US biopharma companies as they race to replenish pipelines and maintain growth trajectories through the 2030s.

Eli Lilly, the world's most valuable pharmaceutical company, announced an agreement to acquire Merida Biosciences in a transaction valued at up to $2.875 billion, representing another significant expansion of the company's drug development pipeline. The deal is structured with a combination of upfront payment and milestone-contingent consideration, reflecting the clinical-stage nature of some of Merida's assets. For Lilly, the acquisition represents a continuation of its strategy to build out its cardiometabolic disease portfolio — the therapeutic area where its GLP-1/GIP dual-agonist drugs Mounjaro (tirzepatide for diabetes) and Zepbound (for obesity) have generated extraordinary commercial success and reshaped global expectations for pharmaceutical revenue growth.

Merida Biosciences brings a set of drug candidates that are expected to complement rather than duplicate Lilly's existing GLP-1 franchise. The company's programs are focused on metabolic regulation pathways that extend beyond the GLP-1 mechanism, potentially enabling Lilly to address patient populations who cannot tolerate or fully respond to current GLP-1 therapies. This is a strategically important gap in the obesity and diabetes treatment landscape: while Mounjaro and Zepbound have demonstrated remarkable clinical efficacy, the market for next-generation metabolic drugs remains enormous and underserved, and Lilly is positioning to maintain category leadership through 2030 and beyond.

The acquisition continues a wave of M&A activity among top-tier US biopharma companies. With patent cliffs approaching on several blockbuster molecules over the next decade, companies like Pfizer, AstraZeneca, and Novo Nordisk are competing aggressively to acquire late-stage clinical assets and diversify revenue streams. For Lilly specifically, the challenge is maintaining its exceptional growth rate — driven primarily by GLP-1 revenues — while building a second pillar of growth through its immunology and oncology portfolios. The Merida deal reinforces the cardiometabolic pillar and suggests Lilly's M&A team is not yet done shopping.

Synthesized from 1 source.